Trump abandons his FDA nominee, and Senate scraps vote on his NSF pick
First reported by Ars Technica ·
You will not get a confirmed FDA commissioner in this administration, and the NSF director role remains vacant.
In a swift turn of events, the Trump administration has withdrawn its nomination of Heidi Overton for the Food and Drug Administration (FDA) commissioner and scrapped a Senate vote for Jim O'Neill, the nominee for the National Science Foundation (NSF). Overton faced widespread criticism from both parties for her controversial stances on vaccines, abortion, and vaping, and for repeatedly evading direct answers during her confirmation hearing. A senior administration official cited a lack of congressional support as the reason for withdrawing Overton. The Senate Health, Education, Labor, and Pensions (HELP) Committee subsequently canceled O'Neill's vote due to concerns over his perceived lack of scientific experience and his role in past administration decisions, including the ousting of a previous CDC director. Committee Chair Senator Bill Cassidy expressed disappointment, stating that leadership and fortitude were needed to stand up for science.
The withdrawal of two high-profile nominees, one for a critical health agency and another for a science funding body, signals significant challenges in the administration's ability to secure Senate confirmation for its appointees. This pattern suggests a potential disconnect between the White House's selection criteria and the vetting process required by the Senate, particularly for roles demanding scientific or public health expertise. The nominees' struggles highlight the intense scrutiny now applied to individuals with past associations with controversial policies, especially concerning public health issues.
The fallout from these withdrawals could impact the operational continuity and strategic direction of both the FDA and the NSF. Without confirmed leadership, these agencies may face delays in implementing new initiatives, addressing pressing scientific challenges, or responding to public health crises. The repeated emphasis on "leadership and fortitude" and "standing up for science" by key senators indicates a growing demand for nominees who can demonstrate independence and a commitment to established scientific consensus over political expediency.
AI-written summary. May contain errors.